


1:16 - what does it mean?



Katherine Philpott
Chief BMS, Cambridge University Hospitals Trust

Antibody titration

- * Antibody titration is performed on patients' samples to support:
 - * The prediction and management of HDFN
 - * Determining cold agglutinins in CHAD
 - * The management of ABO mismatched organ transplant

The prediction and management of HDFN

- * HDFN occurs when maternal IgG antibodies cross the placenta and bind to the corresponding antigen on the fetal red cells
- * The resultant IgG-coated cells interact with fetal macrophages; this facilitates the removal of these cells in the fetal spleen
- * The severity of the disease ranges from mild anaemia to stillbirth
- * Titration of an alloantibody to a red cell antigen is used to measure the level of maternal antibody during pregnancy
- * Generally a titre of <32 is unlikely to result in significant disease; a titre of >32 is considered significant

Cold agglutinins

- * Cold agglutinins occur naturally in nearly everyone
- * Natural cold autoantibodies occur at low titres, usually <64 at 4°C and have no activity at higher temperatures
- * Pathological cold agglutinins (such as with CHAD) occur at titres >64 and react at $28-31^{\circ}\text{C}$
- * Pathological cold agglutinins can cause agglutination and occlusion in the micro-vasculature and initiate haemolysis and eventually chronic anaemia

Organ transplantation

- * According to the NHSBT organ donation website, as of yesterday, 2229 people have received transplants since 1st April 2013 however 7134 people are still waiting
- * A significant proportion will die before a suitable organ becomes available
- * In principle solid organ transplants must be performed from a donor of an ABO compatible blood group
 - * ABO antigens are also expressed on endothelial cells of the transplanted organ
- * However, last year 1068 living donor kidney transplants were carried out, many of them from ABO incompatible donors

ABOi renal transplantation

- * Low levels of antibody appear not to be harmful to transplanted organs
- * Transplantation is safe if anti-donor A or B antibody is, or can be reduced to low levels at the time of transplantation
- * The most important issue to determine is the quantity of anti-donor A or B antibody in the recipients circulation
- * An ABOi transplant can be performed if the titre of anti-donor A or B antibody is <16 , or can be reduced to <16 by antibody removal (plasma exchange or immunoabsorption)
- * ABOi renal transplantation is not normally considered for patients with a starting antibody titre >256


Reminder

- * A titre of <32 is unlikely to result in significant HDFN; a titre of >32 is considered significant
- * Pathological cold agglutinins (such as with CHAD) occur at titres >64 and react at $28-31^{\circ}\text{C}$
- * An ABOi transplant can be performed if the titre of anti-donor A or B antibody is <16 ; ABOi renal transplantation is not normally considered for patients with a starting antibody titre >256

The technique

- * Prepare patients plasma in saline using a doubling dilution method
- * Prepare 0.8% red cell suspension
- * Perform a LISS IAT and a direct agglutination at RT
- * The endpoint is considered as the highest dilution to give a (1+) positive reaction

Which is the 1+ reaction?



Which is the 1+ reaction?



The problem

- * Titrations produce a large disparity of values amongst individuals

Technique	P1	P2
DRT in-house Diamed	64 (32-256)	2 (2-4)
DRT in-house Ortho	128 (32-128)	4 (2-4)
DRT in-house tube	64 (8-256)	4 (2-16)
DRT in-house Immucor	32 (32-32)	4 (4-4)
DRT in-house all (37)	64 (2-256)	4 (2-16)
IAT in-house Diamed	96 (64-256)	8 (4-16)
IAT in-house Ortho	1024 (128-1024)	64 (16-64)
IAT in-house tube	128 (32-256)	6 (4-8)
IAT in-house Immucor	64 (64-128)	8 (8-8)
IAT in-house all (16)	128 (32-1024)	8 (4-64)

Why?

- * Antibody titrations have been notoriously difficult to standardise
 - * Vast inconsistencies in technique and interpretation amongst laboratories and technologists
- * Determining the endpoint
- * Optimal incubation time, temperature and centrifugation speed
- * Zygoty, phenotype, age and concentration of reagent red cells

The consequences

- * HDFN - inaccuracies in testing may lead to the mother missing vital investigations or being subjected to unnecessary interventions
- * Mis-diagnosis of CHAD and subsequent management and/or treatment may be inappropriate
- * ABOi renal transplants - inconsistencies in testing could mean the patient is under or over-treated or not at all

What needs to be done?

- * Standardisation and uniform practice should be emphasised
- * Initial samples should be tested by 2 workers
- * Subsequent samples should be tested alongside the previously tested sample
- * Pipetting technique, changing tips between dilutions to prevent carryover
- * Gel card technique shows less variance than tube testing
- * Automation

Summary

- * Antibody titrations are important in antenatal testing, antibody investigations and performing and monitoring ABOi organ transplants
- * NEQAS results have demonstrated significant variation in results between laboratories
- * Standardisation of technique continues to be elusive
- * Automation has to be the way forward